Study of Gene Modified WT1 (Wilms' Tumor 1)TCR Therapy in MDS and AML Patients
Conditions: Myelodysplastic Syndromes (MDS); Acute Myeloid Leukaemia (AML)Intervention: Genetic: Gene-modified WT1 TCR-transduced T cells intravenous infusionSponsors: Cell Therapy Catapult; Leukaemia Lymphoma Research; Department of Health, United Kingdom; University College, LondonRecruiting - verified September 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials